The determination of changes in the expression of genes for selected specific transcriptional factors in in vitro ductal breast cancer cells under the influence of paclitaxel

• Autorzy: Ziaja-Soltys M. , Rzymowska J.
• Języki publikacji: EN

Abstrakty

EN

This study aimed to determine the changes in the expression of genes for selected specific transcriptional factors that have both activating and repressing functions in in vitro ductal breast cancer cells, under the influence of paclitaxel, applying the microarray technique. The cells are treated with 60 ng/ml and 300 ng/ml doses of paclitaxel that correspond to those applied in breast cancer therapy. About 60 ng/ml doses of paclitaxel cause a statistically significant increase in expression of all the 16 analysed genes coding transcriptional factors, ranging from 1.84-fold (for PO4F2) to 4.65-fold (for LMO4) (p < 0.05) in comparison with the control cells, and enhanced the taxane mechanism of action. The 300 ng/ml doses of paclitaxel cause a cytotoxic effect in the cells. In this article, we argue that these changes in gene expression values may constitute prognostic and predictive factors in ductal breast cancer therapy.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2011
• Tom: 16
• Numer: 4
• Opis fizyczny: p.610-624,fig.,ref.

Twórcy

autor

Ziaja-Soltys M.

• Medical University of Lublin, Department of Biology and Genetics, 20-093 Lublin, Chodzki 4A, Poland

autor

Rzymowska J.

Bibliografia

• 1. Lai, D., Ho, K.C., Hao, Y. and Yang, X. Taxol resistance in breast cancer cells is mediated by the Hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res. 7 (2011) 2728-2738.
• 2. http://zdrowie.org.pl Access from 01.02.2008.
• 3. Benz, C.C. Transcription factors and breast cancer. ERC 5 (1998) 271-282.
• 4. Hannemann, J., Velds, A., Halfwerk, J.B.G., Kreike, B., Peterse, J.L. and van de Vijver, M.J. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res. 8 (2006) R61DOI:10.1186/ bcr1613.
• 5. Rodrigues, N.A., Dillon, D., Carter, D., Parisot, N. and Haffty B.G. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97 (2003) 1393-1403.
• 6. Cleator, S., Parton, M. and Dowsett M. The biology of neoadjuwant chemotherapy for breast cancer. ERC 9 (2002) 183-195.
• 7. Duan, Z., Lamendola D.E., Duan, Y., Yusuf R.Z. and Seiden M.V. Description of paclitaxel resistance-assiciated genes in ovarian and breast cancer cell lines. Cancer Chemoth. Pharm. 5 (2005) 277-285.
• 8. Bodnar, L., Wcisło, G., Miedzińska-Maciejewska, M. and Szczylik, C. Docetaxel and paclitaxel: comparison of their pharmacology and mechanisms of resistance. Contemp. Oncol. 8 (2004) 435-446.
• 9. Crown, J. and O’ Leary, M. The taxanes: an update. Lancet 355 (2000) 1176-1178.
• 10. Dozier, J.H., Hiser, L., Davis, J.A., Thomas, N.S., Tucci, M.A., Benghuzzi, H.A., Frankfurter, A., Coreia, J.J. and Lobert, S. β class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res. 5 (2003) R157-R169.
• 11. Luker, K.E., Pica, Ch.M., Schreiber, R.D. and Piwnica-Worms, D. Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res. 61 (2001) 6540-6547.
• 12. Górecka, K.M., Gawęcki, W. and Szyfer, K. The lack of genotoxic activity of antitumor drug paclitaxel in lymphocytes exposed in vitro to therapeutic drug concentrations. Contemp. Oncol. 7 (2003) 260-263.
• 13. Cooper C.S. Applications of microarray technology in breast cancer research. Breast Cancer Res. 3 (2001) 158-175.
• 14. Bednarski, D. and Firestine, S.M. Regulation of transcription by synthetic DNA-bending agents. Chem. Biol. Chem. 7 (2006) 1715-1721.
• 15. Kummerfeld, S.K. and Teichmann, S.A. DBD: a transcription factor prediction database. Nucleic Acids Res. 34 (2006) D74-D81. DOI:10.1093/ nar/gkj131.
• 16. Stoughton, R.B. Applications of DNA microarrays in biology. Annu. Rev. Biochem. 74 (2005) 53-82.
• 17. Roman, I. [Mikromacierze DNA-perspektywy wykorzystania w badaniach skuteczności i bezpieczeństwa stosowania leków]. Post. Bioch. 54 (2008) 107-113.
• 18. http://www.cancer-info.com, Access from 2007-08-08; Taxol.
• 19. Visvader, J.E., Venter, D., Hahm, K., Santamaria, M., Sum, E.Y., O'Reilly, L., White, D., Williams, R., Armes, J. and Lindeman, G.J. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc. Natl. Acad. Sci. USA 98 (2001) 14452-14457.
• 20. Sum, E.Y., Segara, D., Duscio, B., Bath, M.L., Field, A.S., Sutherland, R.L., Lindeman, G.J. and Visvader, J.E. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc. Natl. Acad. Sci. USA 102 (2005) 7659-7664.
• 21. Li, H., Watts, G.S., Oshiro, M.M., Futscher, B.W. and Domann, F.E. AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells. Oncogene 25 (2006) 5405-5415.
• 22. Stabach, P.R., Thiyagarajan, M.M., Woodfield, G.W. and Weigl R.J. AP2 alpha alters the transcriptional activity and stability of p53. Oncogene 25 (2006) 2148-2159.
• 23. Li, H., Goswami, P.C. and Domann, F.E. AP-2γ induces p21 expression, arrests cell cycle, and inhibits the tumor growth of human carcinoma cells. Neoplasia 8 (2006) 568-577.
• 24. Rakha, E.A., Pinder, S.E., Paish C.E. and Ellis, I.O. Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.l. Br. J. Cancer 91 (2004) 1591-1596.
• 25. Butcher, D.T. and Rodenhiser, D.I. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours. Eur. J. Cancer 43 (2007) 210-219.
• 26. Lee, S.A., Ndisang, D., Patel, C., Dennis, J.H., Faulkes, D.J., D'Arrigo, C., Samady, L., Farooqui-Kabir, S., Heads, R.J., Latchman, D.S. and BudhramMahadeo, V.S. Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter. Cancer Res. 65 (2005) 3072-3080.
• 27. Feldman, R.J., Sementchenko, V.I., Gayed, M., Fraig, M.M. and Watson, D.K. Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. Cancer Res. 63 (2003) 4626-4631.
• 28. Ghadersohi, A. and Sood, A.K. Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. Clin. Cancer Res. 7 (2001) 2731-2738.
• 29. Javed, A., Barnes, G.L., Pratap, J., Antkowiak, T., Gerstenfeld, L.C., van Wijnen, A.J., Stein, J.L., Lian, J.B. and Stein, G.S. Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc. Natl. Acad. Sci. USA 102 (2005) 1454-1459.
• 30. Rowland, B.D., Bernards, R. and Peeper, D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell. Biol. 7 (2005) 1074-1082.
• 31. Mishra, S., Murphy, L.C., Nyomba, B.L. and Murphy, L.J. Prohibitin: a potential target for new therapeutics Trends Mol. Med. 11 (2005) 192-197.
• 32. Koker, M.M. and Kleer, C. p63 expression in breast cancer. A highly sensitive and specific marker of metaplastic carcinoma. Am. J. Surg. Pathol. 28 (2004) 1506-1512.
• 33. Leong, C.O., Vidnovic, N., DeYoung, M.P., Sgroi, D. and Ellisen, L.W. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J. Clin. Invest. 117 (2007) 1370-1380.
• 34. Stefanou, D., Batistatou, A., Nonni, A., Arkoumani, E. and Agnantis, N.J. p63 expression in benign and malignant breast lesions. Histol. Hisopathol. 19 (2004) 465-471.
• 35. Valladares, A., Hernández, N.G., Gómez, F.S., Curiel-Quezada, E., Madrigal-Bujaidar, E., Vergara, M.D., Martínez, M.S. and Arenas Aranda, D.J. Genetic expression profiles and chromosomal alterations in sporadic breast cancer in Mexican women. Cancer Genet. Cytogenet. 170 (2006) 147-151.
• 36. Duriseti, S., Winnard, P.T. Jr., Mironchik, Y., Vesuna, F., Raman, A. and Raman, V. HOXA5 regulates hMLH1 expression in breast cancer cells. Neoplasia 8 (2006) 250-258.
• 37. Zhang, X., Emerald, B.S., Mukhina, S., Mohankumar, K.M., Kraemer, A., Yap, A.S., Gluckman, P.D., Lee, K.O. and Lobie P.E. HOXA1 is required for E-cadherin-dependent anchorage independent survival of human mammary carcinoma cells. J. Biol. Chem. 281 (2006) 6471-6481.
• 38. Albert, T.K., Hanzawa, H., Legtenberg, Y.I., de Ruwe, MJ., van den Heuvel, F.A., Collart M.A., Boelens, R. and Timmers, H.T. Identification of a ubiquitin - protein ligase subunit within the CC4-NOT transcription repressor complex. EMBO J. 21 (2002) 355-364.
• 39. Allen, M.P., Xu, M., Zeng, Ch., Tobet, S.A. and Wierman, M.E. Myocyte enhancer factors-2B and -2C are required for adhesion related kinase repression of neuronal gonadotropin releasing hormone gene expression. J. Biol. Chem. 275 (2000) 39662-39670.
• 40. Raman, V., Martensen, S.A., Reisman, D., Evron, E., Odenwald, W.F., Jaffee, E., Marks, J. and Sukumar, S. Compromised HOXA5 function can limit p53 expression in human breast tumours. Nature 405 (2000) 974-977.
• 41. Lin, X.. and Nelson, W.G. Methyl-CpG-binding domain protein-2 mediates transcriptional repression associated with hypermethylated GSTP1 CpG islands in MCF-7 breast cancer cells. Cancer Res. 63 (2003) 498-504.
• 42. Zhu, Y., Brown, H. N., Zhang, Y., Holford, T.R and Zheng, T. Genotypes and haplotypes of the methyl-CpG- binding domain 2 modify breast cancer risk dependent upon menopausal status. Breast Cancer Res. 7 (2005) R745- R752.
• 43. Zhong, D., Morikawa, A., Guo, L., Colpaert, C., Xiong, L., Nassar, A., Chen, C., Lamb, N., Dong, J.T. and Zhou, W. Homozygous deletion of SMAD4 in breast cancer cell lines and invasive ductal carcinomas. Cancer Biol. Ther. 5 (2006) 601-607.
• 44. Xie, W., Mertens, J.C., Reiss, D.J., Rimm, D.L., Camp, R.L., Haffty, B.G. and Reiss, M. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res. 62 (2002) 497-505.
• 45. Lee, B.C., Lee, T.H., Zagozdzon, R., Avraham, S., Usheva, A. and Avraham, H.K. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF1alpha-mediated breast cancer cell migration. Cancer Res. 65 (2005) 2840-2845.
• 46. Jankowski, M., Krause, A. and Zegarski, W. [Zastosowanie mikromacierzy DNA w leczeniu raka piersi]. Cancer Surg. (e-publ) 1 (2005) 37-41.
• 47. Ramaswamy, S. and Golub, T.R. DNA microarrays in clinical oncology. J. Clin. Oncol. 20 (2002) 1932-1941.
• 48. Murphy, N., Millar, E. and Lee, C.S. Gene expression profiling in breast cancer: towards individualizing patient management. Pathology 37 (2005) 271-277.
• 49. Reis-Filho, J.S., Westbury, C. and Pierga, J.Y. The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol. 59 (2006) 225-231.

Uwagi

PL

Rekord w opracowaniu.